Eli Lilly price target raised to $1,230 from $1,205 at Cantor Fitzgerald

Cantor Fitzgerald analyst Carter Gould raised the firm’s price target on Eli Lilly (LLY) to $1,230 from $1,205 and keeps an Overweight rating on the shares. Eli Lilly’s Q1 call highlighted strong OUS Mounjaro demand with potential upside to raised guidance and encouraging early Foundayo ramp commentary, with improved earnings leverage supporting higher EPS expectations and multiple catalysts-including a potential 2H acceleration and anticipation of retatrutide-helping sustain engagement, the analyst tells investors in a research note.